Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyCicletanine
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Cicletanine
- Accession Number
- DB12766
- Type
- Small Molecule
- Groups
- Investigational
- Description
Cicletanine is under investigation for the treatment of Diabetes, Hypokalemia, Hyponatremia, and Arterial Hypertension.
- Structure
Structure for DB12766 (Cicletanine)
- Synonyms
- Not Available
- Categories
- UNII
- CHG7QC509W
- CAS number
- 89943-82-8
- Weight
- Average: 261.71
Monoisotopic: 261.0556563 - Chemical Formula
- C14H12ClNO2
- InChI Key
- CVKNDPRBJVBDSS-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3
- IUPAC Name
- 3-(4-chlorophenyl)-6-methyl-1H,3H-furo[3,4-c]pyridin-7-ol
- SMILES
- CC1=C(O)C2=C(C=N1)C(OC2)C1=CC=C(Cl)C=C1
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cicletanine. Experimental Acebutolol Acebutolol may increase the hypotensive activities of Cicletanine. Approved, Investigational Acemetacin The therapeutic efficacy of Cicletanine can be decreased when used in combination with Acemetacin. Approved, Experimental, Investigational Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Cicletanine. Approved, Illicit Alfuzosin Alfuzosin may increase the hypotensive activities of Cicletanine. Approved, Investigational Aliskiren Aliskiren may increase the hypotensive activities of Cicletanine. Approved, Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Cicletanine. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Alphaprodine is combined with Cicletanine. Illicit Alprenolol Alprenolol may increase the hypotensive activities of Cicletanine. Approved, Withdrawn Ambrisentan Cicletanine may increase the hypotensive activities of Ambrisentan. Approved, Investigational Amifostine Cicletanine may increase the hypotensive activities of Amifostine. Approved, Investigational Amlodipine Amlodipine may increase the hypotensive activities of Cicletanine. Approved Amphetamine Amphetamine may increase the hypotensive activities of Cicletanine. Approved, Illicit, Investigational Atenolol Atenolol may increase the hypotensive activities of Cicletanine. Approved Avanafil Avanafil may increase the antihypertensive activities of Cicletanine. Approved Barnidipine Cicletanine may increase the antihypertensive activities of Barnidipine. Approved Benazepril Benazepril may increase the hypotensive activities of Cicletanine. Approved, Investigational Bendroflumethiazide Bendroflumethiazide may increase the hypotensive activities of Cicletanine. Approved Benmoxin Benmoxin may increase the hypotensive activities of Cicletanine. Withdrawn Bepridil Bepridil may increase the hypotensive activities of Cicletanine. Approved, Withdrawn Betaxolol Betaxolol may increase the hypotensive activities of Cicletanine. Approved, Investigational Bethanidine Bethanidine may increase the hypotensive activities of Cicletanine. Approved Bezitramide The risk or severity of adverse effects can be increased when Bezitramide is combined with Cicletanine. Experimental, Illicit, Withdrawn Bietaserpine Bietaserpine may increase the hypotensive activities of Cicletanine. Experimental Bimatoprost Bimatoprost may increase the hypotensive activities of Cicletanine. Approved, Investigational Bisoprolol Bisoprolol may increase the hypotensive activities of Cicletanine. Approved Bosentan Bosentan may increase the hypotensive activities of Cicletanine. Approved, Investigational BQ-123 BQ-123 may increase the hypotensive activities of Cicletanine. Investigational Bretylium Bretylium may increase the hypotensive activities of Cicletanine. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Cicletanine. Approved Brofaromine Brofaromine may increase the hypotensive activities of Cicletanine. Experimental Bupranolol Bupranolol may increase the hypotensive activities of Cicletanine. Approved Buprenorphine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Cicletanine. Approved, Illicit, Investigational, Vet Approved Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Cicletanine. Approved, Illicit, Vet Approved Cadralazine Cadralazine may increase the hypotensive activities of Cicletanine. Experimental Cafedrine Cicletanine may increase the hypotensive activities of Cafedrine. Investigational Candesartan Cicletanine may increase the hypotensive activities of Candesartan. Experimental Candesartan cilexetil The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Cicletanine. Approved Candoxatril Candoxatril may increase the hypotensive activities of Cicletanine. Experimental Captopril Captopril may increase the hypotensive activities of Cicletanine. Approved Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Cicletanine. Illicit, Investigational, Vet Approved Caroxazone Caroxazone may increase the hypotensive activities of Cicletanine. Withdrawn Carteolol Carteolol may increase the hypotensive activities of Cicletanine. Approved Carvedilol Carvedilol may increase the hypotensive activities of Cicletanine. Approved, Investigational Celiprolol Celiprolol may increase the hypotensive activities of Cicletanine. Approved, Investigational Chlorothiazide Chlorothiazide may increase the hypotensive activities of Cicletanine. Approved, Vet Approved Chlorthalidone Chlorthalidone may increase the hypotensive activities of Cicletanine. Approved Cilazapril Cilazapril may increase the hypotensive activities of Cicletanine. Approved Clonidine Clonidine may increase the hypotensive activities of Cicletanine. Approved Cloranolol Cicletanine may increase the hypotensive activities of Cloranolol. Experimental Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Cicletanine. Approved, Illicit Cryptenamine Cryptenamine may increase the hypotensive activities of Cicletanine. Approved Cyclopenthiazide Cicletanine may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclothiazide Cyclothiazide may increase the hypotensive activities of Cicletanine. Approved Debrisoquin Debrisoquin may increase the hypotensive activities of Cicletanine. Approved, Investigational Delapril Cicletanine may increase the hypotensive activities of Delapril. Investigational Deserpidine Cicletanine may increase the hypotensive activities of Deserpidine. Approved Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Cicletanine. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cicletanine. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Cicletanine. Approved, Investigational Diazoxide Diazoxide may increase the hypotensive activities of Cicletanine. Approved Diethylnorspermine Diethylnorspermine may increase the hypotensive activities of Cicletanine. Investigational Dihydralazine Dihydralazine may increase the hypotensive activities of Cicletanine. Approved, Investigational Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cicletanine. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cicletanine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cicletanine. Experimental, Illicit Diltiazem Diltiazem may increase the hypotensive activities of Cicletanine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cicletanine. Approved, Illicit Dipyridamole Dipyridamole may increase the antihypertensive activities of Cicletanine. Approved Dorzolamide Dorzolamide may increase the hypotensive activities of Cicletanine. Approved Doxazosin Doxazosin may increase the hypotensive activities of Cicletanine. Approved DPDPE The risk or severity of adverse effects can be increased when DPDPE is combined with Cicletanine. Experimental Efonidipine Efonidipine may increase the hypotensive activities of Cicletanine. Approved, Investigational Enalapril Enalapril may increase the hypotensive activities of Cicletanine. Approved, Vet Approved Enalaprilat Enalaprilat may increase the hypotensive activities of Cicletanine. Approved Endralazine Endralazine may increase the hypotensive activities of Cicletanine. Experimental Epanolol Cicletanine may increase the hypotensive activities of Epanolol. Experimental Epoprostenol Epoprostenol may increase the hypotensive activities of Cicletanine. Approved Eprosartan Eprosartan may increase the hypotensive activities of Cicletanine. Approved Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cicletanine. Approved, Illicit Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Cicletanine. Illicit, Vet Approved Felodipine Felodipine may increase the hypotensive activities of Cicletanine. Approved, Investigational Fenoldopam Fenoldopam may increase the hypotensive activities of Cicletanine. Approved Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Cicletanine. Approved, Illicit, Investigational, Vet Approved Ferulic acid Ferulic acid may increase the hypotensive activities of Cicletanine. Experimental Fosinopril Fosinopril may increase the hypotensive activities of Cicletanine. Approved Fostamatinib Fostamatinib may increase the antihypertensive activities of Cicletanine. Approved, Investigational Furazolidone Furazolidone may increase the hypotensive activities of Cicletanine. Approved, Investigational, Vet Approved Guanabenz Guanabenz may increase the hypotensive activities of Cicletanine. Approved, Investigational Guanadrel Guanadrel may increase the hypotensive activities of Cicletanine. Approved Guanazodine Cicletanine may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Guanethidine may increase the hypotensive activities of Cicletanine. Approved Guanfacine Guanfacine may increase the hypotensive activities of Cicletanine. Approved, Investigational Guanoclor Cicletanine may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Cicletanine may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Cicletanine may increase the hypotensive activities of Guanoxan. Experimental Harmaline Harmaline may increase the hypotensive activities of Cicletanine. Experimental Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Cicletanine. Approved, Illicit, Investigational Hexamethonium Hexamethonium may increase the hypotensive activities of Cicletanine. Experimental Hydracarbazine Hydracarbazine may increase the hypotensive activities of Cicletanine. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Cicletanine. Approved Hydrochlorothiazide Hydrochlorothiazide may increase the hypotensive activities of Cicletanine. Approved, Vet Approved Hydrocodone The risk or severity of adverse effects can be increased when Hydrocodone is combined with Cicletanine. Approved, Illicit Hydroflumethiazide Hydroflumethiazide may increase the hypotensive activities of Cicletanine. Approved, Investigational Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cicletanine. Approved, Illicit Iloprost Iloprost may increase the hypotensive activities of Cicletanine. Approved, Investigational Imidapril Imidapril may increase the hypotensive activities of Cicletanine. Investigational Indapamide Indapamide may increase the hypotensive activities of Cicletanine. Approved Indenolol Indenolol may increase the hypotensive activities of Cicletanine. Withdrawn Indoramin Indoramin may increase the hypotensive activities of Cicletanine. Withdrawn Iproclozide Iproclozide may increase the hypotensive activities of Cicletanine. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Cicletanine. Withdrawn Irbesartan Irbesartan may increase the hypotensive activities of Cicletanine. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypotensive activities of Cicletanine. Approved Isradipine Isradipine may increase the hypotensive activities of Cicletanine. Approved, Investigational Ketanserin Ketanserin may increase the hypotensive activities of Cicletanine. Investigational Ketobemidone The risk or severity of adverse effects can be increased when Ketobemidone is combined with Cicletanine. Approved, Investigational Labetalol Labetalol may increase the hypotensive activities of Cicletanine. Approved Lacidipine Lacidipine may increase the hypotensive activities of Cicletanine. Approved, Investigational Latanoprost Latanoprost may increase the hypotensive activities of Cicletanine. Approved, Investigational Lercanidipine Lercanidipine may increase the hypotensive activities of Cicletanine. Approved, Investigational Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cicletanine. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Cicletanine. Approved Linsidomine Cicletanine may increase the hypotensive activities of Linsidomine. Experimental Lisinopril Lisinopril may increase the hypotensive activities of Cicletanine. Approved, Investigational Lofentanil The risk or severity of adverse effects can be increased when Lofentanil is combined with Cicletanine. Illicit Lofexidine Lofexidine may increase the hypotensive activities of Cicletanine. Approved, Investigational Losartan Losartan may increase the hypotensive activities of Cicletanine. Approved Macitentan Cicletanine may increase the hypotensive activities of Macitentan. Approved Manidipine Manidipine may increase the hypotensive activities of Cicletanine. Approved, Investigational Mebanazine Mebanazine may increase the hypotensive activities of Cicletanine. Withdrawn Mecamylamine Mecamylamine may increase the hypotensive activities of Cicletanine. Approved, Investigational Meptazinol The risk or severity of adverse effects can be increased when Meptazinol is combined with Cicletanine. Experimental Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Cicletanine. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Cicletanine. Approved, Illicit Methoserpidine Cicletanine may increase the hypotensive activities of Methoserpidine. Experimental Methyldopa Methyldopa may increase the hypotensive activities of Cicletanine. Approved Methylene blue Methylene blue may increase the hypotensive activities of Cicletanine. Approved, Investigational Methylphenidate Methylphenidate may decrease the antihypertensive activities of Cicletanine. Approved, Investigational Metipranolol Metipranolol may increase the hypotensive activities of Cicletanine. Approved Metolazone Metolazone may increase the hypotensive activities of Cicletanine. Approved Metoprolol Metoprolol may increase the hypotensive activities of Cicletanine. Approved, Investigational Metyrosine Cicletanine may increase the hypotensive activities of Metyrosine. Approved Mibefradil Mibefradil may increase the hypotensive activities of Cicletanine. Investigational, Withdrawn Minaprine Minaprine may increase the hypotensive activities of Cicletanine. Approved Minoxidil Minoxidil may increase the hypotensive activities of Cicletanine. Approved, Investigational Mirodenafil Mirodenafil may increase the antihypertensive activities of Cicletanine. Investigational Moclobemide Moclobemide may increase the hypotensive activities of Cicletanine. Approved, Investigational Moexipril Moexipril may increase the hypotensive activities of Cicletanine. Approved Molsidomine Molsidomine may increase the hypotensive activities of Cicletanine. Approved, Investigational Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Cicletanine. Approved, Investigational Moxonidine Moxonidine may increase the hypotensive activities of Cicletanine. Approved, Investigational Muzolimine Cicletanine may increase the hypotensive activities of Muzolimine. Experimental Nadolol Nadolol may increase the hypotensive activities of Cicletanine. Approved Naftopidil Naftopidil may increase the hypotensive activities of Cicletanine. Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Cicletanine. Approved Nebivolol Nebivolol may increase the hypotensive activities of Cicletanine. Approved, Investigational Nialamide Nialamide may increase the hypotensive activities of Cicletanine. Withdrawn Nicardipine Nicardipine may increase the hypotensive activities of Cicletanine. Approved, Investigational Nicomorphine The risk or severity of adverse effects can be increased when Nicomorphine is combined with Cicletanine. Experimental Nicorandil Nicorandil may increase the hypotensive activities of Cicletanine. Approved, Investigational Niguldipine Niguldipine may increase the hypotensive activities of Cicletanine. Experimental Nilvadipine Nilvadipine may increase the hypotensive activities of Cicletanine. Approved, Investigational Nimodipine Nimodipine may increase the hypotensive activities of Cicletanine. Approved, Investigational Nisoldipine Nisoldipine may increase the hypotensive activities of Cicletanine. Approved Nitrendipine Nitrendipine may increase the hypotensive activities of Cicletanine. Approved, Investigational Nitroprusside Nitroprusside may increase the hypotensive activities of Cicletanine. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Normethadone is combined with Cicletanine. Approved, Illicit Obinutuzumab Cicletanine may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Cicletanine. Withdrawn Olmesartan Olmesartan may increase the hypotensive activities of Cicletanine. Approved, Investigational Omapatrilat Omapatrilat may increase the hypotensive activities of Cicletanine. Investigational Opium The risk or severity of adverse effects can be increased when Opium is combined with Cicletanine. Approved, Illicit Oxprenolol Oxprenolol may increase the hypotensive activities of Cicletanine. Approved Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Cicletanine. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Cicletanine. Approved, Investigational, Vet Approved Pargyline Pargyline may increase the hypotensive activities of Cicletanine. Approved Penbutolol Penbutolol may increase the hypotensive activities of Cicletanine. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Cicletanine. Approved, Vet Approved Pentolinium Pentolinium may increase the hypotensive activities of Cicletanine. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Cicletanine. Approved, Investigational Perindopril Perindopril may increase the hypotensive activities of Cicletanine. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Cicletanine. Approved Phenazocine The risk or severity of adverse effects can be increased when Phenazocine is combined with Cicletanine. Experimental Phenelzine Phenelzine may increase the hypotensive activities of Cicletanine. Approved Pheniprazine Pheniprazine may increase the hypotensive activities of Cicletanine. Withdrawn Phenoperidine The risk or severity of adverse effects can be increased when Phenoperidine is combined with Cicletanine. Experimental Phenoxybenzamine Phenoxybenzamine may increase the hypotensive activities of Cicletanine. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Cicletanine. Withdrawn Phentolamine Phentolamine may increase the hypotensive activities of Cicletanine. Approved Pinacidil Pinacidil may increase the hypotensive activities of Cicletanine. Approved Pindolol Pindolol may increase the hypotensive activities of Cicletanine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Piritramide is combined with Cicletanine. Approved, Investigational Pirlindole Pirlindole may increase the hypotensive activities of Cicletanine. Approved Pivhydrazine Pivhydrazine may increase the hypotensive activities of Cicletanine. Withdrawn Platelet Activating Factor Platelet Activating Factor may increase the hypotensive activities of Cicletanine. Experimental Polythiazide Polythiazide may increase the hypotensive activities of Cicletanine. Approved Prazosin Prazosin may increase the hypotensive activities of Cicletanine. Approved Procaine Procaine may increase the hypotensive activities of Cicletanine. Approved, Investigational, Vet Approved Procarbazine Procarbazine may increase the hypotensive activities of Cicletanine. Approved, Investigational Propranolol Propranolol may increase the hypotensive activities of Cicletanine. Approved, Investigational Quinapril Quinapril may increase the hypotensive activities of Cicletanine. Approved, Investigational Quinine Quinine may increase the hypotensive activities of Cicletanine. Approved Ramipril Ramipril may increase the hypotensive activities of Cicletanine. Approved Rasagiline Rasagiline may increase the hypotensive activities of Cicletanine. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Cicletanine. Approved Remikiren Remikiren may increase the hypotensive activities of Cicletanine. Approved Rescinnamine Cicletanine may increase the hypotensive activities of Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Cicletanine. Approved, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Cicletanine. Approved, Investigational Riociguat Cicletanine may increase the hypotensive activities of Riociguat. Approved Rituximab Cicletanine may increase the hypotensive activities of Rituximab. Approved Safrazine Safrazine may increase the hypotensive activities of Cicletanine. Withdrawn Saprisartan Saprisartan may increase the hypotensive activities of Cicletanine. Experimental Selegiline Selegiline may increase the hypotensive activities of Cicletanine. Approved, Investigational, Vet Approved Selexipag Selexipag may increase the hypotensive activities of Cicletanine. Approved Sildenafil Sildenafil may increase the antihypertensive activities of Cicletanine. Approved, Investigational Sitaxentan Cicletanine may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sodium phosphate, monobasic Cicletanine may increase the nephrotoxic activities of Sodium phosphate. Approved Spirapril Spirapril may increase the hypotensive activities of Cicletanine. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Cicletanine. Approved, Investigational Tadalafil Tadalafil may increase the antihypertensive activities of Cicletanine. Approved, Investigational Talinolol Talinolol may increase the hypotensive activities of Cicletanine. Investigational Tapentadol The risk or severity of adverse effects can be increased when Tapentadol is combined with Cicletanine. Approved Telmisartan Telmisartan may increase the hypotensive activities of Cicletanine. Approved, Investigational Temocapril Temocapril may increase the hypotensive activities of Cicletanine. Experimental, Investigational Terlipressin Terlipressin may increase the hypotensive activities of Cicletanine. Approved, Investigational Tetrahydropalmatine Tetrahydropalmatine may increase the hypotensive activities of Cicletanine. Investigational Theodrenaline Cicletanine may increase the hypotensive activities of Theodrenaline. Investigational Theophylline Theophylline may increase the antihypertensive activities of Cicletanine. Approved Tibolone Tibolone may increase the hypotensive activities of Cicletanine. Approved, Investigational Ticrynafen Ticrynafen may increase the hypotensive activities of Cicletanine. Withdrawn Tilidine The risk or severity of adverse effects can be increased when Tilidine is combined with Cicletanine. Experimental Timolol Timolol may increase the hypotensive activities of Cicletanine. Approved Tolazoline Tolazoline may increase the hypotensive activities of Cicletanine. Approved, Vet Approved Tolonidine Cicletanine may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Cicletanine. Approved Torasemide Torasemide may increase the hypotensive activities of Cicletanine. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Cicletanine. Approved, Investigational Trandolapril Trandolapril may increase the hypotensive activities of Cicletanine. Approved Tranylcypromine Tranylcypromine may increase the hypotensive activities of Cicletanine. Approved, Investigational Travoprost Travoprost may increase the hypotensive activities of Cicletanine. Approved Treprostinil Treprostinil may increase the hypotensive activities of Cicletanine. Approved, Investigational Trichlormethiazide Trichlormethiazide may increase the hypotensive activities of Cicletanine. Approved, Vet Approved Trimazosin Trimazosin may increase the hypotensive activities of Cicletanine. Experimental Trimethaphan Trimethaphan may increase the hypotensive activities of Cicletanine. Approved, Investigational Udenafil Udenafil may increase the antihypertensive activities of Cicletanine. Approved, Investigational Unoprostone Unoprostone may increase the hypotensive activities of Cicletanine. Approved, Investigational Urapidil Urapidil may increase the hypotensive activities of Cicletanine. Investigational Valsartan Valsartan may increase the hypotensive activities of Cicletanine. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Cicletanine. Approved Vincamine Cicletanine may increase the hypotensive activities of Vincamine. Experimental Vinpocetine Vinpocetine may increase the hypotensive activities of Cicletanine. Investigational Xipamide Cicletanine may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Xylometazoline may increase the hypotensive activities of Cicletanine. Approved, Investigational Yohimbine Yohimbine may decrease the antihypertensive activities of Cicletanine. Approved, Investigational, Vet Approved Zofenopril Cicletanine may increase the hypotensive activities of Zofenopril. Experimental - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Compound
- 54910
- PubChem Substance
- 347828952
- ChemSpider
- 49583
- ChEBI
- 135078
- ChEMBL
- CHEMBL191886
- Wikipedia
- Cicletanine
- ATC Codes
- C03BX03 — Cicletanine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1, 2 Not Yet Recruiting Treatment Arterial Hypertension / Diabetes Mellitus (DM) / Hypokalaemia / Hyponatremias 1 2 Terminated Treatment Pulmonary Arterial Hypertension (PAH) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.727 mg/mL ALOGPS logP 2.8 ALOGPS logP 2.6 ChemAxon logS -2.6 ALOGPS pKa (Strongest Acidic) 8.57 ChemAxon pKa (Strongest Basic) 5.51 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 42.35 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 69.68 m3·mol-1 ChemAxon Polarizability 26.49 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Halobenzenes
- Direct Parent
- Chlorobenzenes
- Alternative Parents
- Methylpyridines / Hydroxypyridines / Aryl chlorides / Heteroaromatic compounds / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organochlorides show 1 more
- Substituents
- Chlorobenzene / Methylpyridine / Hydroxypyridine / Aryl chloride / Aryl halide / Pyridine / Heteroaromatic compound / Dialkyl ether / Ether / Organoheterocyclic compound show 11 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Drug created on October 20, 2016 18:05 / Updated on July 02, 2018 19:41